Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Q: What does CUSIP 98422T100 represent in this 13F holders report?

CUSIP 98422T100 is the security identifier for XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q4 2021?

41 institutional investors reported XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q4 2021. Use the holders table for investor-level position and value details.

CUSIP: 98422T100

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 73,644,024
Total 13F shares: 18,324,586
Share change: +14,123,798
Total reported value: $269,421,063
Price per share: $16.00
Number of holders: 41
Value change: +$225,248,000
Number of buys: 39

Quarterly Holders Quick Answers

What is CUSIP 98422T100?
CUSIP 98422T100 identifies XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2022

Recent filing periods for CUSIP 98422T100:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
SV7 Impact Medicine Fund LP	3/4/5	10%+ Owner	— class O/S missing	3,227,264	$2,678,630	—	26 Oct 2021	3/4/5
Bain Capital Life Sciences Investors, LLC	3/4/5	10%+ Owner	— class O/S missing	2,805,413	$2,328,493	—	08 Dec 2021	3/4/5
James E. Flynn	3/4/5	Possible Member of 10% Group, 10%+ Owner	— class O/S missing	2,287,944	$1,898,994	—	26 Oct 2021	3/4/5
FMR LLC	3/4/5	Other*	— class O/S missing	1,907,670	$1,583,366	—	26 Oct 2021	3/4/5
TAKEDA PHARMACEUTICAL CO LTD	3/4/5	10%+ Owner	— class O/S missing	1,475,121	$1,224,350	—	26 Oct 2021	3/4/5
RiverVest Venture Fund IV, L.P.	3/4/5	10%+ Owner	— class O/S missing	1,441,444	$1,196,399	—	26 Oct 2021	3/4/5
Rock Springs Capital Management LP	3/4/5	10%+ Owner	— class O/S missing	1,256,472	$1,042,872	—	26 Oct 2021	3/4/5
BAY CITY CAPITAL LLC	3/4/5	10%+ Owner	— class O/S missing	1,129,490	$937,477	—	26 Oct 2021	3/4/5
Merck KGaA	3/4/5	10%+ Owner	— class O/S missing	680,825	$565,085	—	26 Oct 2021	3/4/5
FIL Ltd	3/4/5	Other*	— class O/S missing	218,705	$181,525	—	26 Oct 2021	3/4/5
Alexandria Venture Investments, LLC	3/4/5	10%+ Owner	— class O/S missing	166,423	$138,131	—	26 Oct 2021	3/4/5
Simon M. Tomlinson	3/4/5	10%+ Owner	— class O/S missing	131,117	$108,827	—	21 Oct 2021	3/4/5
John Charles Williams	3/4/5	10%+ Owner	— class O/S missing	100,080	$83,066	—	21 Oct 2021	3/4/5
Of Ulrich Rodeck Estate	3/4/5	10%+ Owner	— class O/S missing	100,080	$83,066	—	21 Oct 2021	3/4/5
Timothy P. Clackson	3/4/5	10%+ Owner	— class O/S missing	90,956	$75,493	—	21 Oct 2021	3/4/5
Rachel Humphrey	3/4/5	Director	— class O/S missing	9,444	$7,839	—	21 Oct 2021	3/4/5

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q4 2021

As of 31 Dec 2021, Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by 41 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 18,324,586 shares. The largest 10 holders included Bain Capital Life Sciences Investors, LLC, Atlas Venture Life Science Advisors, LLC, FMR LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), RA CAPITAL MANAGEMENT, L.P., RiverVest Venture Management LLC, Rock Springs Capital Management LP, Soleus Capital Management, L.P., Artal Group S.A., and VANGUARD GROUP INC. This page lists 41 institutional shareholders reporting positions in this security for the Q4 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2021 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2021 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2021 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.